By Fineline Cube Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate (ADC), has received U.S. FDA Orphan Drug Designation (ODD) for three indications: biliary tract cancer, gastric cancer, and pancreatic cancer. The novel ADC, which utilizes antigen-mediated internalization and bystander activity to enhance tumor killing, previously secured IND approvals from both NMPA and FDA in September 2025. The triple ODD validates Huadong’s innovation capabilities and accelerates development in high-unmet-need gastrointestinal malignancies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Designation | Orphan Drug Designation (ODD) – three indications |
| Product | HDM2017 for injection |
| Drug Class | Antibody-drug conjugate (ADC) – Category 1 innovative biological drug |
| Target | Cadherin 17 (CDH17/LI-cadherin) |
| Indications (ODD) | • Biliary tract cancer • Gastric cancer • Pancreatic cancer |
| Developer | Huadong Medicine Co., Ltd (SHE: 000963) – independently developed |
| Prior Approvals | IND cleared by NMPA and FDA (September 2025) for advanced malignant solid tumors |
| Designation Date | 11 Mar 2026 |
Drug Profile & Mechanism
| Attribute | HDM2017 Specification |
|---|---|
| Target | Cadherin 17 (CDH17/LI-cadherin) – cell adhesion molecule overexpressed in GI cancers |
| Architecture | Anti-CDH17 antibody + cleavable linker + cytotoxic payload |
| Mechanism | • Targeting: Antibody identifies CDH17-positive tumor surface antigens • Internalization: Antigen-mediated entry into tumor cells • Payload Release: Intracellular linker cleavage releases cytotoxin • Bystander Effect: Membrane-permeable payload kills neighboring antigen-negative cells |
| Preclinical Profile | • Excellent drug-like properties • Potent anti-tumor activity in CDH17-positive colorectal, pancreatic, gastric models • Well-tolerated in animal studies |
CDH17 Biology:
- Expression Pattern: Highly expressed in gastrointestinal epithelium; upregulated in biliary, gastric, pancreatic, and colorectal cancers
- Tumor Specificity: Limited normal tissue expression reduces on-target/off-tumor toxicity risk
- Internalization: Efficient antigen-mediated uptake enables effective ADC payload delivery
Strategic Value & Market Context
| Factor | Implication |
|---|---|
| Three ODDs | Unusual breadth of orphan designation; demonstrates CDH17 relevance across multiple GI malignancies |
| GI Cancer Burden | • Biliary tract: 20,000 U.S. cases/year • Gastric: 26,000 U.S. cases/year • Pancreatic: 60,000 U.S. cases/year; all with limited targeted therapy options |
| ODD Benefits | 7-year market exclusivity; tax credits; waived FDA application fees; protocol assistance |
| Huadong Innovation | Second innovative ADC (after HDM2024 EGFR/HER3) validates biologics platform; traditional pharma pivot to novel modalities |
| Global Strategy | U.S.-first development pathway; China NMPA parallel track; potential for Fast Track and Breakthrough Therapy designations |
Competitive Landscape
| Competitor | Product | Target | Status | HDM2017 Differentiation |
|---|---|---|---|---|
| AstraZeneca/Daiichi | Enhertu (HER2 ADC) | HER2 | Approved (gastric) | CDH17 vs. HER2; different patient population (HER2-negative gastric) |
| Zymeworks/Jazz | Zanidatamab (HER2 bsAb) | HER2 | Approved (biliary) | ADC mechanism vs. naked antibody; CDH17 targets non-HER2 population |
| Ipsen/Exelixis | Cabometyx (cabozantinib) | Multi-kinase | Approved (pancreatic, biliary) | Targeted ADC vs. broad kinase inhibition; potentially better tolerability |
| Huadong Medicine | HDM2017 | CDH17 | Phase I-ready; triple ODD | First-in-class CDH17 ADC; novel target with broad GI applicability |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase I | 2025-2027 (ongoing) | Safety, tolerability, MTD; CDH17 expression biomarker validation |
| Phase II | 2027-2029 | Expansion in ODD indications (biliary, gastric, pancreatic); efficacy signals |
| Regulatory Strategy | 2029-2030 | Accelerated approval pathway via ODD; potential Breakthrough Therapy designation |
| Combination Studies | 2028+ | With checkpoint inhibitors (PD-1) and chemotherapy backbones |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, orphan drug exclusivity value, and competitive positioning for HDM2017. Actual results may differ due to CDH17 target validation in human trials, manufacturing scale-up, and competitive dynamics in GI cancer ADC development.-Fineline Info & Tech